Statin Therapy
2002; Lippincott Williams & Wilkins; Volume: 105; Issue: 25 Linguagem: Inglês
10.1161/01.cir.0000023397.12047.03
ISSN1524-4539
AutoresAlan C. Yeung, Philip S. Tsao,
Tópico(s)Coronary Interventions and Diagnostics
ResumoHomeCirculationVol. 105, No. 25Statin Therapy Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBStatin TherapyBeyond Cholesterol Lowering and Antiinflammatory Effects Alan C. Yeung, MD and Philip Tsao, PhD Alan C. YeungAlan C. Yeung From Stanford University School of Medicine, Stanford, Calif. and Philip TsaoPhilip Tsao From Stanford University School of Medicine, Stanford, Calif. Originally published25 Jun 2002https://doi.org/10.1161/01.CIR.0000023397.12047.03Circulation. 2002;105:2937–2938Aggressive cholesterol lowering has gradually been adopted by clinicians as part of a standard treatment regimen for patients with documented coronary artery disease, including those who have had recent bypass surgery and acute coronary syndrome.1–3 According to the recently published National Cholesterol Education Program Adult Treatment Panel III (NCEP III) guidelines, 3a those patients who have documented coronary disease should have their LDL cholesterol lowered to less than 100 mg/dL.See p 3017The clinical benefit of statin therapy is primarily attributed to its LDL-lowering (and potentially HDL-elevating) effects. A subgroup analysis, however, of large clinical trials indicates that statin-treated individuals have significantly less cardiovascular disease than patients with comparable serum cholesterol levels.4–6 Subsequently, intriguing experimental data have shown that statins exhibit pleiotropic effects that can beneficially impact occlusive vascular disease, including inhibition of smooth muscle proliferation and platelet aggregation, enhancement of endothelial function, and antiinflammatory actions.7–12 These effects could be due to the fact that mevalonic acid is the precursor of not only cholesterol synthesis but also of many nonsteroidal isoprenoid compounds. These signaling intermediates are thought to be important for the subcellular localization and intracellular trafficking of several membrane-bound proteins. In addition, statins can induce the phosphorylation (and activation) of the serine/threonine protein kinase, Akt. More recently, experimental evidence suggest that statins may also have oncoprotective effects by inducing certain tumor cell types, such as acute myelogenous leukemia, to undergo apoptosis in a sensitive and specific manner.13,14 Also of interest clinically is the fact that statin therapy seems to reduce the risk of bone fracture in retrospective analysis of the Scandinavian Simvastatin Survival Study (4S), as well as in a case-control study15–17 supported by gathering experimental data.18 Thus, it is clear that statins have significant non–cholesterol lowering effects, both in the vascular system and in nonvascular systems.Extensive evidence accumulated over the past 2 decades has demonstrated that the endothelium provides essential vasculoprotective functions. Although the clinical benefits of balloon angioplasty and stent deployment have been well documented, the mechanical nature of the procedures has obvious injurious effects upon the endothelial layer. Thus, it is not surprising that various strategies have been proposed to enhance endothelial regeneration. In the current issue of Circulation, Walter et al,19 under the direction of the late Jeffrey Isner, demonstrate that simvastatin treatment can accelerate reendothelialization after balloon injury and reduce restenosis in the rat carotid model. They subsequently hypothesized that one of the underlying mechanisms may be the enhancement of the mobilization and recruitment of endothelial progenitor cells from bone marrow to the site of injury by statins.To test this idea, the authors performed bone marrow transplantation from Tie2/lacZ mice to lethally irradiated nude mice and rats. Animals receiving statin therapy demonstrated an increased number of b-gal positive cells on the carotid luminal surface. Moreover, simvastatin resulted in elevated numbers of circulating cells that were positive for BS-1 lectin and acetyl low-density lipoprotein (acLDL) uptake, suggestive of endothelial precursor cells (EPCs). In vitro experiments with putative human EPCs determined that incubation with simvastatin caused upregulation of integrins, offering a potential mechanism for their increased adhesiveness to fibronectin-rich areas of balloon injury.Although this provocative study has potential importance for many vasculopathies, there are a few limitations that should be considered. First and foremost is the identification and function of the cells in question. Although it is attractive to think that the lectin/acLDL–positive cells are of bone marrow origin, the possibility that they are endothelial cells that were shed from the vasculature during the isolation procedure cannot be excluded. In addition, because the cells were identified and quantified after 4 days in culture, it may be that simvastatin affects ex vivo EPC proliferation or survival as opposed to mobilization from the bone marrow. It should be noted that the existing literature regarding the effect of statins upon endothelial cell proliferation has been controversial, with studies demonstrating both positive and negative effects.20–22 Of course, if it could be shown that endothelial precursors could be mobilized by statins, the underlying mechanisms would be of tremendous scientific and clinical interest. Furthermore, the function of bone marrow–derived cells compared with existing endothelial cells would be important to determine. For example, would the secretion and activity of humoral mediators be equivalent in the 2 cell types? To that end, factors such as nitric oxide and tissue-type plasminogen activator would be of particular interest because it has been already been established that statins increase the expression of these products in cultured endothelial cells.22–24 Finally, the demonstration of this effect in larger, more clinically relevant models of restenosis is crucial for the eventual translation into clinical medicine. Importantly, it will be necessary to determine whether this effect holds true in the setting of dyslipidemia.Even with these caveats, however, we can speculate on the potential clinical implications of these findings. It is well known that statin therapy in humans reverses endothelial dysfunction as early as 6 months after therapy. Can this be due to enhanced turnover of "healthier" endothelial cells from the bone marrow? The cholesterol-independent plaque-stabilizing effects of statins may also be due in part to enhanced reendothelialization of injured vascular surfaces. In addition, the potential use of bone marrow stem cells for therapeutic angiogenesis has been discussed at great length in both the scientific and lay press. As suggested by the authors, the use of statins in combination of bone marrow cells may enhance incorporation into ischemic tissue and the initiation of angiogenesis.There appears to be an ever-growing list of actions that are attributed to statins beyond their ability to reduce serum cholesterol levels. It remains to be determined, however, which, if any, of these effects are actually clinically important at the dose range used. As with many novel scientific endeavors, the current study19 seems to invoke more questions than answers. Even after his untimely death, Dr Jeffrey Isner continues to challenge our traditional way of thinking and inspire us to strive for a better understanding of how nature operates.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to Dr Alan Yeung, Stanford University Medical Center, #2105 300 Pasteur Dr, Stanford, CA 94305. E-mail [email protected] cvmed.stanford.edu References 1 Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol. 2000; 86: 257–262.CrossrefMedlineGoogle Scholar2 Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation. 2000; 102: 157–165.CrossrefMedlineGoogle Scholar3 Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285: 1711–1718.CrossrefMedlineGoogle Scholar3A Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation. 2002; 105: 152–156.CrossrefMedlineGoogle Scholar4 Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996; 335: 1001–1009.CrossrefMedlineGoogle Scholar5 Massy ZA, Keene WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet. 1996; 347: 102–103.CrossrefMedlineGoogle Scholar6 Packard CJ. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998; 87: 1440–1445.Google Scholar7 Indolfi C, Cioppa A, Stabile E et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol. 2000; 35: 214–221.CrossrefMedlineGoogle Scholar8 Schror K. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterol-lowering agents. Eicosanoids. 1990; 3: 67–73.MedlineGoogle Scholar9 Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995; 332: 488–493.CrossrefMedlineGoogle Scholar10 Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995; 332: 481–487.CrossrefMedlineGoogle Scholar11 Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001; 344: 1959–1965.CrossrefMedlineGoogle Scholar12 Musial J, Undas A, Gajewski P, et al. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol. 2001; 103: 1191–1193.Google Scholar13 Eto M, Kozai T, Cosentino F, et al. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 2002; 105: 1756–1759.LinkGoogle Scholar14 Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000; 6: 1004–1010.CrossrefMedlineGoogle Scholar15 Wong WW, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002; 16: 508–519.CrossrefMedlineGoogle Scholar16 Pedersen TR, Kjekshus J. Statin drugs and the risk of fracture. 4S Group. JAMA. 2000; 284: 1921–1922.Google Scholar17 Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 2000; 355: 2185–2188.CrossrefMedlineGoogle Scholar18 Ohnaka K, Shimoda S, Nawata H, et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun. 2001; 287: 337–342.CrossrefMedlineGoogle Scholar19 Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002; 105;3017–3024.LinkGoogle Scholar20 Vincent L, Chen W, Hong L, et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett. 2001; 495: 159–166.CrossrefMedlineGoogle Scholar21 Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000; 6: 1004–1010.CrossrefMedlineGoogle Scholar22 Weis M, Heeschen C, Glassford AJ, et al. Statins have biphasic effects on angiogenesis. Circulation. 2002; 105: 739–745.CrossrefMedlineGoogle Scholar23 Laufs U, La Fata V, Plutzky J, et al. Upregulation of nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97: 1129–1135.CrossrefMedlineGoogle Scholar24 Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 199; 272: 31725–31729.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By van Kempen B, Ferket B, Hofman A, Spronk S, Steyerberg E and Hunink M (2012) Do Different Methods of Modeling Statin Treatment Effectiveness Influence the Optimal Decision?, Medical Decision Making, 10.1177/0272989X12439754, 32:3, (507-516), Online publication date: 1-May-2012. Chen W, Tang F, Xie B, Chen S, Huang H and Liu P (2012) Amelioration of atherosclerosis by tanshinone IIA in hyperlipidemic rabbits through attenuation of oxidative stress, European Journal of Pharmacology, 10.1016/j.ejphar.2011.10.040, 674:2-3, (359-364), Online publication date: 1-Jan-2012. Moussavian M, Scheuer C, Schmidt M, Kollmar O, Wagner M, von Heesen M, Schilling M and Menger M (2010) Multidrug donor preconditioning prevents cold liver preservation and reperfusion injury, Langenbeck's Archives of Surgery, 10.1007/s00423-010-0668-4, 396:2, (231-241), Online publication date: 1-Feb-2011. Karamouzian S, Eskandary H, Saeed A, Reihani-Kermani H, Aboosaeedi H, Malekpoor-Afshar R, Safizade H and Eskandari M (2011) Effect of Atorvastatin on Angiogenesis in Degenerated Intervertebral Disc in Rat, Spine, 10.1097/BRS.0b013e3181d4e15a, 36:22, (1824-1828), Online publication date: 1-Oct-2011. Kubo M and Egashira K (2009) Therapeutic neovascularization by nanotechnology-mediated drug delivery system, Folia Pharmacologica Japonica, 10.1254/fpj.133.139, 133:3, (139-143), . Nagila A, Permpongpaiboon T, Tantrarongroj S, Porapakkham P, Chinwattana K, Deakin S and Porntadavity S (2009) Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status, Pharmacological Reports, 10.1016/S1734-1140(09)70146-X, 61:5, (892-898), Online publication date: 1-Sep-2009. Gurgun C, Yavuzgil O and Kultursay H (2009) Statins in the treatment of heart failure, International Journal of Cardiology, 10.1016/j.ijcard.2007.08.013, 132:1, (124-126), Online publication date: 1-Feb-2009. Kolovou G, Vasiliadis I, Anagnostopoulou K and Cokkinos D (2008) Simvastatin: Two Decades in a Circle, Cardiovascular Therapeutics, 10.1111/j.1527-3466.2008.00047.x, 26:2, (166-178), Online publication date: 1-Jun-2008. Gürgün C, Ildızlı M, Yavuzgil O, Sin A, Apaydın A, Çınar C and Kültürsay H (2008) The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure, International Journal of Cardiology, 10.1016/j.ijcard.2006.11.152, 123:2, (102-107), Online publication date: 1-Jan-2008. Lewis G (2008) Materials, fluid dynamics, and solid mechanics aspects of coronary artery stents: A state‐of‐the‐art review, Journal of Biomedical Materials Research Part B: Applied Biomaterials, 10.1002/jbm.b.31028, 86B:2, (569-590), Online publication date: 1-Aug-2008. Lee S, Kim Y, Kim Y and Yoon B (2008) Atorvastatin enhances hypothermia-induced neuroprotection after stroke, Journal of the Neurological Sciences, 10.1016/j.jns.2008.07.029, 275:1-2, (64-68), Online publication date: 1-Dec-2008. Chauhan A, Hahn S, Gartner S, Pardo C, Netesan S, McArthur J and Nath A (2006) Molecular programming of endothelin‐1 in HIV‐infected brain: role of Tat in up‐regulation of ET‐1 and its inhibition by statins, The FASEB Journal, 10.1096/fj.06-7054com, 21:3, (777-789), Online publication date: 1-Mar-2007. Sheu J, Chang L, Chiang C, Sun C, Chang N, Youssef A, Wu C, Lee F and Yip H (2007) Impact of Diabetes on Cardiomyocyte Apoptosis and Connexin43 Gap Junction Integrity Role of Pharmacological Modulation, International Heart Journal, 10.1536/ihj.48.233, 48:2, (233-245), . Puccetti L, Pasqui A, Bruni F, Pastorelli M, Ciani F, Palazzuoli A, Pontani A, Ghezzi A and Auteri A (2007) Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment, International Journal of Cardiology, 10.1016/j.ijcard.2006.07.045, 119:1, (41-47), Online publication date: 1-Jun-2007. Chambers B and Roberts N (2007) Asymptomatic carotid artery stenosis, Current Treatment Options in Cardiovascular Medicine, 10.1007/s11936-007-0001-x, 9:2, (81-89), Online publication date: 1-May-2007. Zhang Y, Zhang H, Hua S, Ma L, Chen C, Liu X, Jiang L, Yang H, Zhang P, Yu D, Guo Y, Tan X and Liu J (2007) Identification of two herbal compounds with potential cholesterol-lowering activity, Biochemical Pharmacology, 10.1016/j.bcp.2007.06.020, 74:6, (940-947), Online publication date: 1-Sep-2007. McGillicuddy F, Lynch I, Rochev Y, Burke M, Dawson K, Gallagher W and Keenan A (2006) Novel "plum pudding" gels as potential drug-eluting stent coatings: Controlled release of fluvastatin, Journal of Biomedical Materials Research Part A, 10.1002/jbm.a.30839, 79A:4, (923-933) McGillicuddy F, O'Toole D, Hickey J, Gallagher W, Dawson K and Keenan A (2006) TGF-β1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells, Vascular Pharmacology, 10.1016/j.vph.2006.03.002, 44:6, (469-475), Online publication date: 1-Jun-2006. Chang L, Sun C, Wang C, Youssef A, Wu C, Chua S and Yip H (2006) Downregulation of Peroxisme Proliferator Activated Receptor Gamma Co-Activator 1α in Diabetic Rats, International Heart Journal, 10.1536/ihj.47.901, 47:6, (901-910), . Yip H, Youssef A, Chua S, Hung W, Chen Y, Yeh K, Wu C and Hang C (2006) Re-Elevation of High-Sensitivity C-Reactive Protein but not the von Willebrand Factor After Withdrawing Atorvastatin Therapy in Patients With Unstable Angina Undergoing Coronary Artery Stenting A Kinetic Study, International Heart Journal, 10.1536/ihj.47.501, 47:4, (501-509), . Aukrust P, Yndestad A, Smith C, Sandberg W, Ueland T, Wæhre T, Halvorsen B, Gullestad L and Damås J (2005) Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation, Expert Opinion on Pharmacotherapy, 10.1517/14656566.6.13.2169, 6:13, (2169-2180), Online publication date: 1-Oct-2005. Ceccato F and Paira S (2005) Compromiso de grandes vasos en arteritis de células gigantes, Seminarios de la Fundación Española de Reumatología, 10.1016/S1577-3566(05)74485-7, 6:2, (53-63), Online publication date: 1-Jun-2005. Wu S, Shiang J, Lin S, Wu T, Huang W, Chiou K and Liu C (2005) Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins, Heart and Vessels, 10.1007/s00380-005-0836-6, 20:5, (217-223), Online publication date: 15-Sep-2005. Choudhury R, Lee J and Greaves D (2005) Mechanisms of Disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis, Nature Clinical Practice Cardiovascular Medicine, 10.1038/ncpcardio0195, 2:6, (309-315), Online publication date: 1-Jun-2005. Yip H, Hung W, Yang C, Chen Y, Cheng C, Chen S and Yeh K (2005) Serum Concentrations of High-Sensitivity C-Reactive Protein Predict Progressively Obstructive Lesions Rather Than Late Restenosis in Patients With Unstable Angina Undergoing Coronary Artery Stenting, Circulation Journal, 10.1253/circj.69.1202, 69:10, (1202-1207), . Aukrust P, Yndestad A, Wæhre T, Gullestad L, Halvorsen B and Damås J (2014) Inflammation in coronary artery disease: potential role for immunomodulatory therapy, Expert Review of Cardiovascular Therapy, 10.1586/14779072.3.6.1111, 3:6, (1111-1124), Online publication date: 1-Nov-2005. Ulstad V (2004) Prevention of coronary heart disease in women Women's Health in Mid-Life, 10.1017/CBO9780511545672.012, (209-224) Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J and Jiang J (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins, Nature Medicine, 10.1038/nm1135, 10:12, (1344-1351), Online publication date: 1-Dec-2004. McLean A and Le Couteur D (2004) Aging Biology and Geriatric Clinical Pharmacology, Pharmacological Reviews, 10.1124/pr.56.2.4, 56:2, (163-184), Online publication date: 1-Jun-2004. Kalantar-Zadeh K, Block G, Horwich T and Fonarow G (2004) Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure, Journal of the American College of Cardiology, 10.1016/j.jacc.2003.11.039, 43:8, (1439-1444), Online publication date: 1-Apr-2004. Nuenninghoff D, Hunder G, Christianson T, McClelland R and Matteson E (2003) Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: A population-based study over 50 years, Arthritis & Rheumatism, 10.1002/art.11353, 48:12, (3522-3531), Online publication date: 1-Dec-2003. Reichert K, Pereira do Carmo H, Galluce Torina A, Diógenes de Carvalho D, Carvalho Sposito A, de Souza Vilarinho K, da Mota Silveira-Filho L, Martins de Oliveira P, Petrucci O and Lionetti V (2016) Atorvastatin Improves Ventricular Remodeling after Myocardial Infarction by Interfering with Collagen Metabolism, PLOS ONE, 10.1371/journal.pone.0166845, 11:11, (e0166845) June 25, 2002Vol 105, Issue 25 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000023397.12047.03PMID: 12081982 Originally publishedJune 25, 2002 KeywordscholesterolEditorialsstatinsPDF download Advertisement
Referência(s)